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Introduction
Clathrin-coated vesicles (CCVs) are important transport inter-
mediates in all eukaryotic cells. Their coats consist of two ma-
jor components: clathrin, which provides a stabilizing scaffold, 
and heterotetrameric adaptor protein (AP) complexes, which at-
tach the clathrin to the membrane and select the vesicle cargo 
(Robinson, 2004). There are at least two AP complexes associ-
ated with CCVs: AP-1, which functions in transport between 
the TGN and endosomes (although there is some question about 
directionality), and AP-2, which functions in clathrin-mediated 
endocytosis (Traub, 2005; Bonifacino and Rojas, 2006; Foote 
and Nothwehr, 2006).
Although it was originally assumed that clathrin and AP 
complexes were all that was necessary to make a CCV, it is now 
apparent that CCV formation is much more complex. New 
components of the machinery are continually being discovered, 
including various “alternative adaptors” and proteins that con-
tribute to other stages of the CCV cycle (Traub, 2005). Thus, 
  although the most abundant components of CCVs are known, 
many questions remain regarding the initiation of vesicle for-
mation, cargo selection, budding, scission, uncoating, and trans-
port. Clearly, a complete knowledge of the protein composition 
of CCVs would greatly advance our understanding of clathrin-
mediated traffi  cking.
In recent years, organelle proteomics has emerged as 
a powerful tool to guide cell biological research (McDonald 
and Yates, 2000; Andersen and Mann, 2006; Dunkley et al., 
2006), and two studies have so far been published on the CCV 
  proteome. Blondeau et al. (2004) and Girard et al. (2005) 
prepared CCV-enriched fractions from rat brain and liver, 
 respectively,  and  identifi  ed proteins by tandem mass   spectrometry 
(MS/MS). In both studies, an impressive degree of CCV 
  enrichment was achieved (73–89% vesicle homogeneity, as 
judged by electron microscopy), and numerous proteins were 
identifi  ed. However, neither study could distinguish which 
of the identifi  ed proteins were true constituents of CCVs and 
which were copurifying contaminants.
Because it is impossible to prepare completely pure CCVs, 
the challenge becomes fi   nding unbiased criteria that allow 
one to identify genuine CCV components. With such criteria 
at hand, the purity of the preparation is no longer critical. Here, 
we introduce a novel criterion: the dependence of a protein on 
clathrin to be present in a CCV fraction. By pairing cell biologi-
cal tools with state-of-the-art quantitative proteomics  techniques, 
we develop a strategy for identifying bona fi  de CCV proteins 
from human tissue culture cells.
Results and discussion
Unbiased proteomic analysis of CCVs
A CCV-enriched fraction was prepared from HeLa cells using 
an established protocol (Hirst et al., 2004), and the same proce-
dure was performed on cells that had been depleted of clathrin 
heavy chain (CHC) by siRNA knockdown. Such cells have been 
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shown to contain no detectable clathrin-coated budding profi  les 
or vesicles (Motley et al., 2003), so the prediction is that the 
“mock CCV” fraction from these cells should be devoid of 
CCVs but should still contain proteins that contaminate CCV 
preparations from control cells. Thus, a comparison between 
the two fractions should reveal genuine CCV proteins as those 
present only (or mainly) in the control CCV fraction and con-
taminants as those equally present in both fractions (Fig. 1 a).
To validate the approach, control and mock CCV fractions 
were analyzed by Western blotting (Fig. 1 b). All of the known 
CCV components that we tested, including coat proteins (e.g., 
CHC, AP-1 and AP-2 subunits, and epsinR) and cargo proteins 
(e.g., cation-independent mannose 6-phosphate receptor [CIMPR] 
and transferrin receptor), were enriched in our CCV prepara-
tions compared with whole cell homogenate (the homogenate 
lanes contain approximately four times as much protein as the 
CCV lanes) and were absent or depleted from mock CCVs. In 
contrast, known contaminants (e.g., elongation factor 2) were 
equally present in control and mock CCVs. Thus, our compara-
tive proteomics approach should allow us to distinguish bona 
fi  de CCV constituents from irrelevant proteins that copurify. 
  Interestingly, we consistently observed differences in the degree 
of enrichment and depletion of AP-1 and AP-2 subunits. AP-1 
subunits were more highly enriched in CCVs relative to cell 
  homogenate, and they were also more strongly depleted from 
the mock CCVs, suggesting that our preparation favors intra-
cellular, nonendocytic CCVs.
As a fi   rst step toward analyzing the CCV proteome, 
control and mock CCV fractions were separated by 1D SDS-
PAGE and stained with Coomassie blue (Fig. 1 c). The two 
fractions have similar protein patterns, indicating that CCV-
enriched preparations from control cells are heavily contami-
nated with non-CCV material. However, four high molecular 
weight proteins appear to be depleted from mock CCVs (Fig. 
1 c, arrows). These proteins were analyzed by MALDI-TOF 
(matrix-assisted laser desorption/ionization time-of-fl  ight) and 
identifi  ed as CHC (which comigrates with glycogen debranch-
ing enzyme), CIMPR, the β1 subunit of AP-1, and transferrin 
receptor. Thus, the 1D SDS-PAGE data confi  rm the results of 
the Western blot, but they offer insuffi  cient resolution to ana-
lyze more minor constituents.
Analysis of CCVs by 2D difference gel 
electrophoresis (DIGE)
To identify additional CCV components, control and mock 
CCV fractions were compared by 2D DIGE (Borner et al., 
2003). The two fractions were labeled with different fl  uorescent 
dyes, pooled, and analyzed in single 2D gels. A representative 
gel is shown in Fig. 2, with the control CCV fraction in red and 
the mock CCV fraction in green. The spot pattern was highly 
reproducible and allowed a clear distinction between proteins 
present in both fractions (yellow spots) and proteins depleted 
from the mock CCVs (red spots), which are likely to be genuine 
CCV components. Proteins were excised from the gels and 
identifi  ed by liquid chromatography (LC)–MS/MS (Fig. 2 c). 
Several prominent red spots were found to correspond to known 
clathrin coat components (clathrin heavy and light chains, β1, 
μ1A, β2, epsinR, and CVAK104) and fusion machinery (N-
 ethylmaleimide–sensitive fusion protein [NSF]), lending further 
support to the validity of the approach. Again, we consistently 
observed more AP-1 than AP-2, as indicated by the relative in-
tensities of the β1 and β2 spots.
Several other proteins implicated in membrane traffi  c were 
also identifi  ed as red spots. These include fi  ve sorting nexins, 
Snx1, Snx2, Snx5, Snx6, and Snx9, none of which had been 
identifi  ed in either of the two previous proteomic analyses of 
CCVs. Snx1 and Snx2 are putative components of the mamma-
lian retromer complex, which functions in retrograde traffi  c 
from endosomes to the TGN (Seaman, 2004). Another retromer 
component, mVPS35, also appears as a red spot. mVPS35 was 
also found in the proteomic analyses of brain and liver CCVs 
(Blondeau et al., 2004; Girard et al., 2005), but at the time, the 
physiological relevance of this observation was unclear.
The majority of the spots on the 2D gel are yellow, indi-
cating that they are equally abundant in control and mock CCVs. 
Several of the yellow spots were identifi  ed by LC-MS/MS and 
found to correspond to irrelevant proteins. Thus, the 2D DIGE 
method enabled us to distinguish between genuine CCV com-
ponents and contaminants and to identify 15 proteins that are 
largely depleted from the mock CCVs, including several novel 
CCV proteins.
Analysis of CCVs by quantitative 
mass spectrometry
An inherent disadvantage of 2D gels is the poor resolution of 
hydrophobic proteins. Hence, it is likely that integral membrane 
proteins, including CCV cargo, are strongly underrepresented 
Figure 1.  Unbiased comparative proteomics of CCVs. (a) Schematic rep-
resentation of the experimental approach. (b) Control and mock CCV frac-
tions were prepared and analyzed by Western blotting ( 7.5  μg 
protein/lane for homogenates and  2 μg for CCV fractions). (c) Compari-
son of control and mock CCV fractions by 1D SDS-PAGE. Proteins were 
identiﬁ  ed by mass spectrometry. EF, elongation factor; GDE, glycogen 
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in our DIGE analysis. To overcome this limitation, as well as to 
increase the sensitivity of our screen, we used iTRAQ (isobaric 
tags for relative and absolute quantifi  cation), a gel-free quanti-
tative proteomics method (Ross et al., 2004). Control and mock 
CCVs were digested with trypsin and labeled with iTRAQ 
tags, which bind to free amines. The labeled peptides were 
then pooled into a single sample, and the peptide mixture was 
fractionated by cation exchange chromatography and analyzed 
by LC-MS/MS. The tags are chemically similar and isobaric 
(i.e., have the same mass), so identical peptides that originally 
came from different samples and therefore have different tags 
coelute from the LC and are simultaneously analyzed by pre-
cursor ion scanning. However, fragmentation of the iTRAQ 
tags during MS/MS results in different signature peaks. Integration 
of these peaks allows the determination of the relative abun-
dance of a given peptide in the original samples. In turn, this 
allows the quantifi  cation of the parent protein from which the 
peptide was derived.
Using this approach, 522 proteins were identifi  ed  and 
quantifi  ed from control and mock CCV fractions (Table S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200607164/DC1). 
To determine which proteins were depleted from mock CCVs, 
the mean relative abundance of proteins in control and mock 
CCVs was calculated and expressed as a ratio (control/mock 
CCVs). High ratios correspond to proteins depleted from 
mock CCVs and thus to candidate CCV proteins. Proteins were 
ranked according to this ratio in descending order.
A plot of normalized ratio over rank (Fig. 3) reveals that 
the majority of proteins did not change substantially between 
mock and control CCVs; in fact, 378 proteins have ratios 
  between 0.5 and 1.5 (i.e., changes in relative abundance of 
50% or less). However,  10% of the proteins were signifi  -
cantly depleted from the mock CCVs (ratios between  2.0 
and 12.2; Fig. 3, left). Although the differences between con-
trol and mock CCVs are often not as great as predicted by our 
other data, the curve has the expected biphasic shape, and the 
fi  gure of 10% depleted proteins agrees well with our 1D and 
2D gels.
Figure 2.  2D DIGE analysis of CCVs. A CCV-
enriched fraction (control) and a mock CCV 
fraction (CHC knockdown) were labeled 
with Cy3 and Cy5, respectively, pooled, and 
  analyzed in a single 2D gel. (a) Control CCV 
fraction. (b) CHC-knockdown mock CCV 
  fraction. (c) Overlay of a and b with control CCVs 
in red and mock CCVs in green. Yellow spots 
correspond to proteins with similar abundance in 
both fractions. White arrowheads indicate pro-
teins that were identiﬁ  ed by mass   spectrometry. 
EF, elongation factor; MVP, major vault protein; 
TfR, transferrin receptor.
Figure 3. iTRAQ  quantiﬁ   cation of control and mock CCV fractions. 
  Fractions were tagged with iTRAQ reagents, and the relative abundance 
of identiﬁ   ed proteins in control and mock CCVs was ascertained by 
quantifying the iTRAQ tags. The 522 proteins were sorted by decreasing 
ratios of control/mock CCVs. The ﬁ  gure shows a normalized plot of ratio 
over rank. Error bars indicate standard deviations from means of two 
technical replicates.JCB • VOLUME 175 • NUMBER 4 • 2006  574
Table I. Results of iTRAQ analysis
Rank Protein ID Protein name Previously 
identiﬁ  ed?
Established
CCV protein?
Mascot score Peptides
quantiﬁ  ed
Control/mock ratio SD
Top 53 proteins
1 gi|30582397 AP-1 σ1A  96 1 12.24 5.13
2 gi|32451593 CHC17  1826 30 6.27 1.46
3 gi|30582933 DNase II (lysosomal) new new 63 1 5.01 1.09
4 gi|1363934 Dynamin-2 new  569 11 4.83 1.31
5 gi|41016993 EpsinR/Enthoprotin  478 10 4.59 1.31
6 gi|17028334 AP-1 μ1A  379 8 4.59 1.08
7 gi|56203491 TPD52L1 new new 104 1 4.45 1.24
8 gi|12643391 AP-1 γ  540 18 4.37 1.05
9 gi|3294548 Cathepsin Z 
(lysosomal)
new new 102 2 4.10 1.19
10 gi|38570101 Unknown  protein 
(RAB-GAP domain)
new new 45 3 4.05 0.98
11 gi|1335854 Clathrin heavy chain
homologue (CHC22)
 new 558 1 3.84 1.09
12 gi|17402231 Clathrin light chain a  231 9 3.81 1.02
13 gi|2143260 PI 3-kinase C2α  822 11 3.62 1.03
14 gi|55662275 CI-Mannose 6-
phosphate receptor
 668 14 3.53 0.85
15 gi|70608172 TPD52 new new 160 1 3.52 0.85
16 gi|25090897 CALM  258 5 3.43 0.94
17 gi|21903712 Carboxypeptidase D  406 7 3.41 0.93
18 gi|116505 Clathrin light chain b  171 9 3.39 0.77
19 gi|2226273 TGN46 new  163 1 3.30 0.75
20 gi|33150596 AP-1 σ1B new  49 1 3.20 0.74
21 gi|55663531 Syntaxin 6  new 121 1 3.15 0.78
22 gi|13477131 Sorting nexin 9 new  260 6 3.07 0.79
23 gi|56205909 Rab4A  319 4 2.78 0.71
24 gi|62287155 NECAP-1  66 1 2.75 0.86
25 gi|182516 Ferritin light subunit  131 3 2.67 0.57
26 gi|14043007 AP-1 β1  1020 8 2.60 0.73
27 gi|2827434 Sorting nexin 2 new new 403 4 2.58 0.54
28 gi|9716092 Sortilin new  125 2 2.53 0.77
29 gi|66932909 Pumilio 1 RNA binding — 105 1 2.46 0.74
30 gi|8546849 CD-Mannose   152 5 2.44 0.63
6-phosphate receptor
31 gi|67477390 Inositolpolyphosphate 
5-phosphatase OCRL-1
new  581 8 2.40 0.61
32 gi|2337920 Syntaxin 7  new 220 3 2.38 0.61
33 gi|47125326 Ferritin heavy chain  84 5 2.37 0.77
34 gi|55958410 Argininosuccinate 
synthetase
metabolism — 176 5 2.37 0.62
35 gi|8922952 Cappuccino new new 73 1 2.36 0.79
36 gi|47086495 BLOC-1, subunit 3  new new 96 3 2.35 0.58
37 gi|56205243 Auxilin  150 3 2.33 0.63
38 gi|7920147 NSF  63 1 2.33 0.64
39 gi|4557469 AP-2 β2   831 7 2.32 0.66
40 gi|57162630 AP-3 μ3A new new 90 1 2.31 0.46
41 gi|15489411 AP-2 μ2   121 4 2.31 0.67
42 gi|54695838 Rab5C  311 5 2.29 0.55
43 gi|62751805 D19 new new 88 2 2.29 0.47
44 gi|15214676 Unknown protein 
(putative Rab interactor)
new new 62 1 2.28 0.50
45 gi|4433649 Syntaxin 8  new 122 2 2.21 0.52
46 gi|13543973 IMP (inosine monophos-
phate dehydrogenase) 2
metabolism — 510 15 2.17 0.55
47 gi|9557955 Sorting nexin 5 new new 206 3 2.15 0.61
48 gi|17375734 cyclin G–associated 
  kinase/auxilin2
 288 3 2.12 0.64COMPARATIVE PROTEOMICS OF CCVS • BORNER ET AL. 575
To determine a useful (albeit arbitrary) cutoff, we chose 
the lowest ranking (i.e., least depleted) AP-1 or AP-2 subunit, 
as APs are known CCV proteins that show clear depletion 
from mock CCVs. This was the α subunit of AP-2 (rank 53; 
ratio 2.03). By prediction, all proteins with higher ranks 
(i.e., ranks 1–52) should correspond to bona fi  de CCV pro-
teins (Table I). Indeed, out of the top 53 proteins, about half 
are established CCV components, including clathrin heavy 
and light chains, subunits of the AP-1 and AP-2 complexes, 
cargo molecules, alternative adaptors, and other machinery. 
Of the remaining proteins, four could be classifi  ed as likely 
false positives, based on their known functions in RNA 
binding or metabolism. The others are novel candidate 
CCV components.
Evaluation of the comparative 
proteomics approach
Because all of the known CCV-associated proteins that we 
identifi  ed in our proteomics analyses were signifi  cantly de-
pleted in the mock CCV fraction, it is likely that other proteins 
that behave in a similar manner are also genuinely CCV associ-
ated. Nevertheless, there are at least two possible sources of 
false positives that need to be considered. First, expression lev-
els of other proteins may be decreased by clathrin knockdown, 
causing them to appear depleted from the mock CCVs. 
Although none of the proteins that we analyzed by Western 
blotting were signifi  cantly depleted from whole cell homoge-
nates, this may account for the four obvious false positives 
identifi  ed by iTRAQ. Second, we cannot exclude the possibility 
that blocking CCV-mediated traffi   cking may interfere with 
other pathways. For example, if clathrin knockdown prevents 
the formation of another type of transport intermediate, which 
is normally also present in the CCV fraction, it will appear 
  depleted from mock CCVs. However, there is currently no 
  evidence to support this possibility.
The iTRAQ analysis may also have produced a few false 
negatives. The control/mock ratios of known CCV proteins are 
generally lower than we expected from our other data,  suggesting 
that there may be additional genuine CCV components among 
proteins with ranks between 54 and  100. However, because 
of overlap with background proteins, such proteins were only in-
cluded in the list of identifi  ed CCV proteins (Table S2, avail  able 
at http://www.jcb.org/cgi/content/full/jcb.200607164/DC1) 
when they showed clear depletion from mock CCVs by Western 
blotting and/or 2D DIGE.
How do our data compare with the two other proteomic 
analyses of CCVs? The studies on brain and liver both focused 
on optimizing the CCV preparation method to minimize the 
number of false positive identifi  cations (Blondeau et al., 2004; 
Girard et al., 2005). In both cases, the yield and purity of the 
Table I. Results of iTRAQ analysis (continued)
Rank Protein ID Protein name Previously 
identiﬁ  ed?
Established 
CCV protein?
Mascot score Peptides 
quantiﬁ  ed
Control/mock ratio SD
49 gi|15214696 Glucosamine (N-acetyl)-
6-sulfatase (lysosomal)
new new 162 4 2.11 0.58
50 gi|13431563 Huntingtin-interacting 
protein 1 related (Hip1R)
 210 1 2.09 0.81
51 gi|1184699 tyrosyl-tRNA synthetase RNA-binding — 47 1 2.06 0.61
52 gi|30582345 Snapin new new 48 1 2.05 0.53
53 gi|19913414 AP-2 α  388 7 2.03 0.46
Selected additional proteins
88 gi|23512245 AP-3 β3A new new 438 9 1.47 0.34
94 gi|12654697 Transferrin receptor  953 20 1.46 0.38
114 gi|32880009 AP-3 σ3A new new 57 1 1.33 0.46
155 gi|5442368 AP-4 σ4 — — 76 1 1.20 0.29
192 gi|37675283 AP-4 ε — — 90 3 1.11 0.22
196 gi|6580116 Glycogen-debranching 
enzyme
metabolism — 1898 98 1.10 0.26
197 gi|56204938 AP-4 β4 — — 69 2 1.10 0.26
252 gi|976227 26S proteasome subunit 
p45
proteasome — 905 28 1.01 0.24
270 gi|31108 EF-2 ribosome — 544 13 0.98 0.22
279 gi|16306837 TCP1, subunit 5 (ε) TCP complex — 689 26 0.95 0.21
520 gi|15990478 Major vault protein 
(MVP)
Vault complex — 838 20 0.15 0.03
Control and mock CCV fractions were prepared as in Fig. 1 and analyzed by iTRAQ (Fig. 3). Identiﬁ  ed proteins were ranked based on their relative abundance in 
control and mock CCVs; a high rank corresponds to a high ratio of control/mock CCVs and, thus, to candidate CCV proteins. Shown are the top-ranking 53 proteins 
(ratio >2.0), some representative contaminants (ratios near 1), and some other proteins of interest. The fourth column indicates whether a protein had been previously 
identiﬁ  ed by CCV proteomics in Blondeau et al. (2004) or Girard et al. (2005). The Mascot score reﬂ  ects the conﬁ  dence with which a protein was identiﬁ  ed; a score 
>35 indicates >95% conﬁ  dence of identiﬁ  cation. “Peptides quantiﬁ  ed” indicates how many iTRAQ-labelled peptides were used for the quantiﬁ  cation. “Control/mock 
ratio” corresponds to the relative abundance of a protein in control and mock CCVs; the ratio is the mean of two technical replicates. The proteins can be found in 
the National Center for Biotechnology Information database. Likely false positives among high ranking proteins are in italics. See Table S1 (available at http://www.
jcb.org/cgi/content/full/jcb.200607164/DC1) for a complete list of the proteins identiﬁ  ed.JCB • VOLUME 175 • NUMBER 4 • 2006  576
CCV fractions were higher than we achieved using HeLa cells, 
but because neither study used unbiased criteria to identify gen-
uine CCV proteins, it is diffi  cult to compare their results quanti-
tatively with ours. Nevertheless, as expected, the CCVs from 
all three sources show an overlapping composition, including 
clathrin heavy and light chains, adaptors, and abundant acces-
sory factors such as NSF and cyclin G–associated kinase (Traub, 
2005). Some of the promising candidate CCV proteins identi-
fi  ed in the two previous studies are not depleted from our mock 
CCV fraction, including myoferlin, various annexins, and Vac14, 
suggesting that they may in fact be contaminants (Table S1). 
There are also several hits from the two previous studies that are 
clearly physiologically relevant, such as epsin, Eps15, Numb, 
and the asialoglycoprotein receptor, which we did not fi  nd in 
the present study, either because they are cell type specifi  c or 
because they are associated with endocytic CCVs, which are 
underrepresented in the HeLa cell CCV fraction.
AP complexes
One notable feature of the HeLa cell CCV preparation is the 
high AP-1/AP-2 ratio. AP-1 is more enriched over whole cell 
homogenate than AP-2, it is more abundant than AP-2, and it is 
more strongly depleted from the mock CCV fraction than AP-2. 
There are probably at least two reasons for this phenomenon. 
First, although HeLa cells appear to contain at least as many 
plasma membrane as intracellular CCVs (based on immuno-
fl  uorescence and electron microscopy; Motley et al., 2003), we 
have found that most of the plasma membrane–associated 
clathrin remains tenaciously attached to cell remnants upon ho-
mogenization (Hirst et al., 2004). Thus, it is likely that the ma-
jority of the AP-2–containing CCVs are discarded in our fi  rst 
low-speed centrifugation step. Second, many of the smooth 
vesicles that contaminate our CCV fraction are derived from 
the plasma membrane (e.g., the transferrin receptor is a major 
component of our mock CCVs), and because AP-2 is recruited 
onto the plasma membrane even in the absence of clathrin 
(Motley et al., 2003), it is likely to be associated with these 
contaminating vesicles. Together, these observations probably 
explain why AP-2 subunits cluster near the lower end of the 
top-ranking proteins in our iTRAQ analysis (Table I, ranks 39, 
41, and 53), whereas subunits of the AP-1 complex are clus-
tered among the highest-ranking proteins (ranks 1, 6, 8, 20, and 
26), showing similar ratios to clathrin heavy and light chains 
(ranks 2, 12, and 18). 
This differential depletion of AP-1 and AP-2 can be 
  exploited to interpret the results of the iTRAQ analysis and to 
assign other proteins in Table I to either the AP-1 or the AP-2 
pathway. The highest-ranking component of AP-2 is β2 (rank 39). 
Thus, as a rough approximation, proteins with ranks higher 
than 39 should be on the AP-1 pathway, and those that fall 
  betweens ranks 39 and 53 should be on the AP-2 pathway. 
  Supporting this notion, essentially all proteins known to func-
tion with AP-1 that were identifi  ed here are among the top 35 
ranking proteins, including epsinR, PI 3-kinase C2α, and both 
mannose 6-phosphate receptors. The results are less clear-cut 
for the AP-2 cluster because it partially overlaps with the AP-3 
cluster (see below).
The clustering approach predicts that other high-ranking 
proteins in Table I, such as syntaxins 6 and 7, are also associated 
with TGN/endosomal CCVs. It suggests that some proteins 
with known functions in endocytosis, such as dynamin-2 and 
Snx9, may also function in intracellular CCV traffi  cking, a pos-
sibility that is supported by immunofl  uorescence studies  (Soulet 
et al., 2005). The presence of two lysosomal enzymes, DNase II 
and cathepsin Z, in the AP-1 cluster may provide some insights 
into the directionality of AP-1–mediated traffi  cking. Lysosomal 
enzymes travel from the TGN to lysosomes via endosomal in-
termediates and are not recycled. Because DNase II and cathep-
sin Z cocluster with AP-1, our results support a role for AP-1 in 
forward transport.
AP-1 and AP-2 belong to a family that includes two other 
complexes, AP-3 and AP-4, neither of which are enriched in 
CCVs purifi  ed from brain (Simpson et al., 1996; Hirst et al., 
1999), although several studies suggest that AP-3 participates in 
clathrin-mediated traffi  cking (Dell’Angelica et al., 1998; Peden 
et al., 2002, 2003). Subunits of both AP-3 and AP-4 complexes 
were identifi  ed in the iTRAQ analysis, with consistently higher 
ratios for the AP-3 subunits than for the AP-4 subunits (Table I). 
Western blots of control and mock CCVs show that both com-
plexes are enriched in CCV fractions, but that only AP-3 is 
Figure 4.  Western blots of selected proteins. Blots of control and mock 
CCV fractions were probed with antibodies against AP-3, AP-4, retromer, 
and BLOC-1 subunits (a) or with various SNARE antibodies (b). Loading 
was as in Fig. 1.COMPARATIVE PROTEOMICS OF CCVS • BORNER ET AL. 577
  depleted from the mock CCVs (Fig. 4 a). Thus, it appears that 
AP-3 indeed plays a role in CCV traffi  cking, whereas AP-4 is a 
contaminant. This example illustrates that neither the presence 
nor the enrichment of a protein in a CCV preparation is suffi  -
cient evidence for its specifi  c association with CCVs and fur-
ther highlights the discriminating power of our comparative 
proteomics approach.
Other CCV components
Subunits of two other protein complexes involved in membrane 
traffi  c, retromer and BLOC-1, were also identifi  ed as candidate 
CCV components. Western blots probed with antibodies against 
the retromer-associated sorting nexin Snx1 and the retromer 
subunit mVPS26 show similar levels of enrichment in the CCV 
fraction over the whole cell homogenate and similar levels of 
depletion from the mock CCV fraction, confi  rming the iTRAQ 
data (Fig. 4 a). BLOC-1 consists of at least eight subunits 
(Dell’Angelica, 2004), seven of which were found in the iTRAQ 
analysis, with ratios ranging from 1.25 to 2.36. Western blots 
probed with an antibody against the eighth subunit, pallidin, 
show that this protein is also moderately depleted from mock 
CCVs (Fig. 4 a). Thus, all eight of the known BLOC-1 subunits 
behave like bona fi  de CCV components. BLOC-1 has recently 
been shown to interact both physically and genetically with AP-3 
(Di Pietro et al., 2006), and the similar ratios of BLOC-1 and 
AP-3 subunits in the iTRAQ analysis suggest that BLOC-1 may 
depend on AP-3 for its association with CCVs.
Among the membrane proteins that showed more than 
twofold depletion in the mock CCV fraction are three post-
Golgi SNAREs: syntaxins 6, 7, and 8. SNAREs are essential for 
the fusion of vesicles with their target organelles, and they are 
frequently used as markers to defi  ne membrane compartments, 
but little is known about how they traffi  c through the secretory 
and endocytic pathways. Peden et al. (2001) showed by Western 
blotting that several post-Golgi SNAREs are highly enriched in 
CCVs from rat liver, and the identifi  cation of three syntaxins in 
our iTRAQ analysis suggested that many SNAREs may use 
clathrin-mediated transport. To test this hypothesis, Western 
blots of control and mock CCV fractions were screened with a 
panel of 16 SNARE antibodies (Fig. 4 b). SNAREs involved in 
traffi  c between the ER and Golgi (syntaxin 17 and Sec22) or in 
exocytosis (syntaxins 2, 3, and 4 and SNAP23) showed little or 
no enrichment in the CCV fraction and were unaffected by 
CHC knockdown. However, all of the SNARES that have been 
localized to the TGN, endosomes, and/or lysosomes, including 
  syntaxins 6, 7, 8, and 16; vti1 a and b; VAMPs 3, 4, and 7; and 
SNAP29, were found to be enriched in control CCVs and de-
pleted from mock CCVs.
One of the most strongly depleted proteins in our iTRAQ 
analysis of mock CCVs is CHC22, a homologue of conven-
tional CHC that is predominantly expressed in muscle (Liu 
et al., 2001). The two CHC isoforms are 85% identical, but 
it is unlikely that CHC22 would be targeted by our 21-base 
siRNA, because its mRNA contains eight mismatches. Although 
it has been proposed that CHC22 is not associated with CCVs 
(Liu et al., 2001), our observations suggest that it is in fact a 
CCV component.
The proteomic analysis also identifi  ed fi  ve novel proteins 
of unknown function in the CCVs. Features of these proteins 
suggest that they too are bona fi  de CCV components. Two of 
the proteins, gi38570101 and gi15214676, have domains pre-
dicted to interact with rabs, which are known regulators of 
membrane traffi  c. Another protein, D19, is an SH3 domain–
containing protein related to intersectin, a protein involved in 
endocytosis. The other two proteins, TPD52L1 and TPD52, are 
members of the D52 family of tumor proteins, which has been 
implicated in the secretory and endocytic pathways (Boutros 
et al., 2004). Thus, all of these proteins may perform important 
regulatory roles in clathrin-mediated traffi  cking, and we are 
currently investigating their functions.
Outlook: comparative 
subcellular proteomics
We have introduced an unbiased criterion to identify CCV 
  proteins. This criterion is easily applicable to novel proteins, even 
outside a proteomic investigation. Simple Western blotting can 
be used to probe control and mock CCVs for a protein of inter-
est to determine whether it is a bona fi  de CCV component.
Apart from identifying novel CCV proteins, we have de-
veloped a method whose scope can be expanded to investigate 
the function of individual CCV components. For example, one 
could knock down specifi  c adaptors to see which cargo proteins 
are lost from CCVs (Hirst et al., 2004). Similarly, knockdown or 
overexpression of accessory proteins may affect CCV composi-
tion, and this could be monitored by iTRAQ. Such an approach 
is not limited to studies on CCVs. Other organelles could also be 
analyzed by 2D DIGE or iTRAQ, using either siRNA knock-
downs or HRP-induced compartment ablation to generate mock 
organelle fractions. Thus, the comparative proteomics   approach 
described in the present study could be used to gain insights not 
only into CCVs but into other parts of the cell as well.
Materials and methods
RNA interference and CCV preparations
siRNA duplexes against target cDNAs were purchased from Dharmacon. 
CHC knockdown was performed using a custom-made duplex described 
by Motley et al. (2003). HeLa cells were transfected using Oligofectamine 
(Invitrogen) in the presence of 10% fetal calf serum; the ﬁ  nal concentration 
of siRNA was 10 nM. For effective knock down, two sequential transfec-
tions were performed on days 1 and 3. Experiments were performed 2 d 
after the second transfection (day 5). CCV-enriched fractions and mock 
CCVs were prepared from control and CHC knockdown HeLa cells as de-
scribed by Hirst et al. (2004), with minor modiﬁ  cations to the protocol.
Gels, mass spectrometry, and iTRAQ
SDS-PAGE and Western blotting were performed according to standard 
protocols. Detailed descriptions of 2D DIGE analysis, iTRAQ analysis, 
mass spectrometric identiﬁ  cation of proteins, and a list of antibodies used 
in this study are provided in the supplemental text and Table S3 (available 
at http://www.jcb.org/cgi/content/full/jcb.200607164/DC1).
Online supplemental material
The supplemental text provides a detailed explanation of iTRAQ and 
DIGE and a protocol for the preparation of CCVs. Table S1 provides 
a complete list of proteins identiﬁ   ed and quantiﬁ   ed by iTRAQ. Table 
S2 provides a summary of CCV proteins identiﬁ   ed in this study by 
  different methods. Table S3 provides a list of antibodies used in this 
study. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200607164/DC1.JCB • VOLUME 175 • NUMBER 4 • 2006  578
We thank Matthew Seaman, Esteban Dell’Angelica, and Andrew Peden for 
antibodies, and Paul Luzio, John Kilmartin, and members of the Robinson labo-
ratory for helpful discussions.
This work was supported by grants from the Wellcome Trust and the 
Medical Research Council.
Submitted: 31 July 2006
Accepted: 13 October 2006
References
Andersen, J.S., and M. Mann. 2006. Organellar proteomics: turning inventories 
into insights. EMBO Rep. 7:874–879.
Blondeau, F., B. Ritter, P.D. Allaire, S. Wasiak, M. Girard, N.K. Hussain, 
A. Angers, V. Legendre-Guillemin, L. Roy, D. Boismenu, et al. 2004. 
Tandem MS analysis of brain clathrin-coated vesicles reveals their criti-
cal involvement in synaptic vesicle recycling. Proc. Natl. Acad. Sci. USA. 
101:3833–3838.
Bonifacino, J.S., and P. Rojas. 2006. Retrograde transport from endosomes to the 
trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7:568–579.
Borner, G.H.H., K.S. Lilley, T.J. Stevens, and P. Dupree. 2003. Identifi  cation 
of glycosylphosphatidylinositol-anchored proteins in Arabidopsis. A pro-
teomic and genomic analysis. Plant Physiol. 132:568–577.
Boutros, R., S. Fanayan, M. Shehata, and J.A. Byrne. 2004. The tumor   protein 
D52 family: many pieces, many puzzles. Biochem. Biophys. Res. Commun. 
325:1115–1121.
Dell’Angelica, E.C. 2004. The building BLOC(k)s of lysosomes and related 
organelles. Curr. Opin. Cell Biol. 16:458–464.
Dell’Angelica, E.C., J. Klumperman, W. Stoorvogel, and J.S. Bonifacino. 
1998. Association of the AP-3 adaptor complex with clathrin. Science. 
280:431–434.
Di Pietro, S.M., J.M. Falcon-Perez, D. Tenza, S.R. Setty, M.S. Marks, G. Raposo, 
and E.C. Dell’angelica. 2006. BLOC-1 interacts with BLOC-2 and the 
AP-3 complex to facilitate protein traffi  cking on endosomes. Mol. Biol. 
Cell. 17:4027–4038.
Dunkley, T.P., S. Hester, I.P. Shadforth, J. Runions, T. Weimar, S.L. Hanton, 
J.L. Griffi  n, C. Bessant, F. Brandizzi, C. Hawes, et al. 2006. Mapping 
the  Arabidopsis organelle proteome. Proc. Natl. Acad. Sci. USA. 
103:6518–6523.
Foote, C., and S.F. Nothwehr. 2006. The clathrin adaptor complex 1 directly 
binds to a sorting signal in Ste13p to reduce the rate of its traffi  cking to 
the late endosome of yeast. J. Cell Biol. 173:615–626.
Girard, M., P.D. Allaire, P.S. McPherson, and F. Blondeau. 2005. Non-
  stoichiometric relationship between clathrin heavy and light chains 
  revealed by quantitative comparative proteomics of clathrin-coated vesicles 
from brain and liver. Mol. Cell. Proteomics. 4:1145–1154.
Hirst, J., N.A. Bright, B. Rous, and M.S. Robinson. 1999. Characterization of a 
fourth adaptor-related protein complex. Mol. Biol. Cell. 10:2787–2802.
Hirst, J., S.E. Miller, M.J. Taylor, G.F. von Mollard, and M.S. Robinson. 2004. 
EpsinR is an adaptor for the SNARE protein Vti1b. Mol. Biol. Cell. 
15:5593–5602.
Liu, S.H., M.C. Towler, E. Chen, C.Y. Chen, W. Song, G. Apodaca, and F.M. 
Brodsky. 2001. A novel clathrin homolog that co-distributes with cyto-
skeletal components functions in the trans-Golgi network. EMBO J. 
20:272–284.
McDonald, W.H., and J.R. Yates III. 2000. Proteomic tools for cell biology. 
Traffi  c. 1:747–754.
Motley, A., N.A. Bright, M.N.J. Seaman, and M.S. Robinson. 2003. Clathrin-
mediated endocytosis in AP-2-depleted cells. J. Cell Biol. 162:909–918.
Peden, A.A., G.Y. Park, and R.H. Scheller. 2001. The di-leucine motif of vesicle-
associated membrane protein 4 is required for its localization and AP-1 
binding. J. Biol. Chem. 276:49183–49187.
Peden, A.A., R.E. Rudge, W.W.Y. Lui, and M.S. Robinson. 2002. Assembly and 
function of AP-3 complexes in cells expressing mutant subunits. J. Cell 
Biol. 156:327–336.
Peden, A.A., V. Oorschot, B.A. Hesser, C.D. Austin, R.H. Scheller, and J. 
Klumperman. 2004. Localization of the AP-3 adaptor complex defi  nes a 
novel endosomal exit site for lysosomal membrane proteins. J. Cell Biol. 
164:1065–1076.
Robinson, M.S. 2004. Adaptable adaptors for coated vesicles. Trends Cell Biol. 
14:167–174.
Ross, P.L., Y.L.N. Huang, J.N. Marchese, B. Williamson, K. Parker, S. Hattan, N. 
Khainovski, S. Pillai, S. Dey, S. Daniels, et al. 2004. Multiplexed protein 
quantitation in Saccharomyces cerevisiae using amine-reactive isobaric 
tagging reagents. Mol. Cell. Proteomics. 3:1154–1169.
Seaman, M.N. 2004. Cargo-selective endosomal sorting for retrieval to the Golgi 
requires retromer. J. Cell Biol. 165:111–122.
Simpson, F., M.A. West, N.A. Bright, L.S. Newman, R. Darnell, and M.S. 
Robinson. 1996. A novel adaptor-related protein complex. J. Cell Biol. 
133:749–760.
Soulet, F., D. Yarar, M. Leonard, and S.L. Schmid. 2005. SNX9 regulates dyna-
min assembly and is required for effi  cient clathrin-mediated endocytosis. 
Mol. Biol. Cell. 16:2058–2067.
Traub, L.M. 2005. Common principles in clathrin-mediated sorting at the Golgi 
and the plasma membrane. Biochim. Biophys. Acta. 1744:415–437.